Browse by Section 100 Item List

Highly Specialised Drugs Program (Private Hospital)

For Pharmaceutical Benefits Scheme (PBS) Highly Specialised Drugs prescribed through private hospitals, claiming and approval of authority prescriptions is administered by Services Australia. Highly Specialised Drugs prescribed in private hospitals are Authority Required items. Application for authorisation can be made by either:

  • posting an Authority Prescription form and other application form(s), where applicable to Services Australia
  • using the form upload facility in Health Professional Online Services (HPOS)
  • using the Online PBS Authorities system (see www.servicesaustralia.gov.au/HPOS)
  • using the Services Australia free-call service for PBS Complex Drugs Programs enquiries (1800 700 270) or
  • using the appropriate Streamlined code.

Prescribers must quote the provider number of the hospital when applying. Maximum quantities and repeats for Highly Specialised Drugs are listed in the PBS Schedule. Authority approvals are required for prescriptions where the dose is above the determined maximum quantity and/or number of repeats.

Private hospital prescriptions for Highly Specialised Drugs can be dispensed by an approved private hospital dispensary or by a community pharmacy. A patient will be required to pay a contribution for each supply of a highly specialised drug at the same rate as the PBS.

The remuneration rates for Highly Specialised Drugs prescribed through private hospitals comprise the normal PBS ready-prepared dispensing fee plus a mark-up ascertained as follows:

  • 10% for drugs with an ex-manufacturer price of less than $40
  • $4 for drugs with an ex-manufacturer price of between $40 and $100
  • 4% for drugs with an ex-manufacturer price of between $100.01 and $1000
  • $40 for drugs with an ex-manufacturer price of greater than $1000.

Reciprocal Health Care Agreement – Where a patient is entitled to be treated as an eligible person as a visitor from a country with which Australia has entered into a Reciprocal Health Care Agreement, the supply will be limited to the original prescription only. Repeat prescriptions for these patients are not permitted.

  • Legend
  • MPMedical Practitioner
  • NPNurse Practitioner
Prescriber code Item code Name, manner of administration and form & strength Max qty
packs
Max qty
units
No. of
repeats
MP 13705H ABATACEPTabatacept 250 mg injection, 1 vial 3 3 5
MP 9621J ABATACEPTabatacept 250 mg injection, 1 vial 1 1 0
MP 12443X ADALIMUMABadalimumab 20 mg/0.2 mL injection, 2 x 0.2 mL syringes 1 2 0
MP 13292N ADALIMUMABadalimumab 20 mg/0.2 mL injection, 2 x 0.2 mL syringes 1 2 5
MP 12396K ADALIMUMABadalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL syringes 1 2 0
MP 13210G ADALIMUMABadalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL syringes 1 2 5
MP 12349Y ADALIMUMABadalimumab 20 mg/0.4 mL injection, 0.4 mL syringe 2 2 5
MP 12439Q ADALIMUMABadalimumab 20 mg/0.4 mL injection, 0.4 mL syringe 2 2 0
MP 14276J ADALIMUMABadalimumab 20 mg/0.4 mL injection, 2 x 0.4 mL syringes 1 2 0
MP 14285W ADALIMUMABadalimumab 20 mg/0.4 mL injection, 2 x 0.4 mL syringes 1 2 5
MP 12368Y ADALIMUMABadalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices 1 2 5
MP 9680L ADALIMUMABadalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices 1 2 0
MP 12335F ADALIMUMABadalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices 1 2 0
MP 13229G ADALIMUMABadalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices 1 2 5
MP 12384T ADALIMUMABadalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes 1 2 5
MP 9679K ADALIMUMABadalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes 1 2 0
MP 10243D ALEMTUZUMABalemtuzumab 12 mg/1.2 mL injection, 1.2 mL vial 5 5 0
MP 10246G ALEMTUZUMABalemtuzumab 12 mg/1.2 mL injection, 1.2 mL vial 3 3 0
MP 12180C AMBRISENTANambrisentan 10 mg tablet, 30 1 30 5
MP 9649W AMBRISENTANambrisentan 10 mg tablet, 30 1 30 5
MP 12201E AMBRISENTANambrisentan 5 mg tablet, 30 1 30 5
MP 9648T AMBRISENTANambrisentan 5 mg tablet, 30 1 30 5
MP 10263E ANAKINRAanakinra 100 mg/0.67 mL injection, 28 x 0.67 mL syringes 1 28 5
MP 14189T ANIFROLUMABanifrolumab 300 mg/2 mL injection, 2 mL vial 1 1 5
MP 11688E APOMORPHINEapomorphine hydrochloride hemihydrate 30 mg/3 mL injection, 5 x 3 mL cartridges 20 100 5
MP 11083H APOMORPHINEapomorphine hydrochloride hemihydrate 100 mg/20 mL injection, 5 x 20 mL vials 18 90 5
MP 10971K APOMORPHINEapomorphine hydrochloride hemihydrate 50 mg/10 mL injection, 5 x 10 mL syringes 36 180 5
MP 11475Y APOMORPHINEapomorphine hydrochloride hemihydrate 30 mg/3 mL injection, 5 x 3 mL pen devices 20 100 5
MP 9640J APOMORPHINEapomorphine hydrochloride hemihydrate 50 mg/5 mL injection, 5 x 5 mL ampoules 36 180 5
MP 13317X AVATROMBOPAGavatrombopag 20 mg tablet, 30 1 30 5
MP 12784W AZACITIDINEazacitidine 100 mg injection, 1 vial 14 14 2
MP 13033Y AZACITIDINEazacitidine 100 mg injection, 1 vial 14 14 5
MP 13038F AZACITIDINEazacitidine 100 mg injection, 1 vial 14 14 2
MP 13039G AZACITIDINEazacitidine 100 mg injection, 1 vial 14 14 2
MP 13040H AZACITIDINEazacitidine 100 mg injection, 1 vial 14 14 5
MP 6100C AZACITIDINEazacitidine 100 mg injection, 1 vial 14 14 2
MP 6138C AZACITIDINEazacitidine 100 mg injection, 1 vial 14 14 5
MPNP 6221K AZITHROMYCINazithromycin 600 mg tablet, 8 2 16 5